Quantcast

Latest CrystalGenomics Inc. Stories

2011-05-31 20:40:00

SEOUL, South Korea, May 31, 2011 /PRNewswire/ -- CrystalGenomics, Inc. (Seoul, Korea) and CG Pharmaceuticals, Inc. (Emeryville, California), a biopharmaceutical company with 3 clinical stage candidates, has announced that the first patient has been enrolled for a Phase 2b clinical study of CG100649, CrystalGenomics' clinical stage novel NSAID candidate, in patients with knee or hip osteoarthritis (OA). CG100649 is a first-in-class NSAID drug candidate that is a dual inhibitor of COX-2 and...

2011-05-11 20:26:00

SEOUL, Korea, May 11, 2011 /PRNewswire/ -- CrystalGenomics, Inc., a biopharmaceutical company with 3 clinical stage candidates, has announced today that the draft Clinical Study Report (CSR) from CG400549's Phase I Multiple Ascending Dose (MAD) Study has just been received. CG400549 is a potential first-in-class antibiotic candidate targeting the fatty acid biosynthesis enzyme FabI, a critical enzyme in generating bacterial membrane and has a novel chemical structure which has never been...

2010-10-06 08:00:00

SEOUL, South Korea, Oct. 6 /PRNewswire/ -- CrystalGenomics, Inc. (www.cgxinc.com), a biopharmaceutical company with drug discovery and development capabilities, has just announced its plan to jointly conduct an investigational preclinical research project with The University of Texas MD Anderson Cancer Center. The purpose of this research is to explore the potential anti-tumor effects of CG100649, CrystalGenomics' clinical stage novel NSAID candidate, which is being developed as an...

2010-10-04 08:00:00

SEOUL, South Korea, Oct. 4 /PRNewswire/ -- CrystalGenomics, Inc. (Seoul, Korea) and CG Pharmaceuticals, Inc. (Emeryville, California), a drug discovery and development biopharmaceutical company, has announced that Dr. William Schmidt, its Vice President of Clinical Development, has been invited to present a talk on "Development of CG100649, Tissue-selective Dual Inhibitor of COX-2 and Carbonic Anhydrase for Treatment of Osteoarthritis" at Arrowhead's upcoming 4th Annual Pain Therapeutics...

2010-09-14 08:00:00

SEOUL, South Korea, Sept. 14 /PRNewswire/ -- CrystalGenomics, Inc. (www.cgxinc.com), a leading biopharmaceutical company developing novel therapeutics announced today that it has been nominated for this year's Scrip Awards (www.scripawards.com) in the category of Best Company in an Emerging Market. The winner will be announced at the 6th Annual Scrip Award ceremony on November 4th in London. The Scrip Awards are one of the industry's most prestigious contested awards to highlight the...

2010-05-28 05:15:00

SEOUL, South Korea, May 28 /PRNewswire/ -- CrystalGenomics, Inc. (www.cgxinc.com), a leading biopharmaceutical company developing novel small molecule therapeutics announced today that it will merge with BexPharm, a specialty pharmaceutical company that imports and distributes foreign market approved drugs in Korea. The main motive for this merger is to provide necessary tools and infrastructures for CrystalGenomics to transform into an integrated biopharmaceutical company with discovery,...

2010-05-10 20:51:00

SEOUL, South Korea, May 10 /PRNewswire/ -- CrystalGenomics, Inc., a novel drug R&D company announced today that the Phase I SAD (Single Ascending Dose) study for its novel antibiotic candidate, CG400549, has been successfully completed in Europe. CG400549 is a potential first-in-class antibiotic candidate targeting ENR (Enoyl-acyl carrier protein reductase, which is a critical enzyme in generating bacterial membrane) as it has novel chemical structure which has never been used as an...

2010-01-13 12:36:00

SEOUL, South Korea, Jan. 13 /PRNewswire/ -- AstraZeneca and CrystalGenomics (KOSDAQ: CRYSTAL [A083790]) announced today that they have entered into a research collaboration to discover and develop a novel anti-infective for use as a potential antibacterial agent. Under the terms of this agreement, Korea-based CrystalGenomics will receive research funding from AstraZeneca for two years. CrystalGenomics will also be eligible to receive future milestones and royalty payments associated with...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related